Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is: To explore the potential role of Tripterygium wilfordii plus steroid in the treatment of membranous nephropathy.

To investigate the safety and tolerability of Tripterygium wilfordii plus steroid

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhi-Hong Liu, M.D.
• Treatments: Prednisone; Tacrolimus

Criteria

Inclusion Criteria:

1. Biopsy-proven idiopathic membranous nephropathy

2. Nephrotic syndrome with proteinuria ( > 3.5 g/day) and serum albumin < 30 g/dl

3. Age 18-65 years with informed consent

Exclusion Criteria:

1. Patient with elevated serum creatinine concentration

2. Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days

3. Active/serious infection

4. Patient with hepatitis B surface antigen or who is hepatitis C antibody positive

5. Patient who is diabetic

6. Patient is allergic or intolerant to macrolide antibiotics or tacrolimus